Danish pharmaceutical giant Novo Nordisk has launched Wegovy®, a once-weekly injectable medication for chronic weight management, in India. Uniquely, Wegovy® is the first and only treatment in the country approved not only for weight loss but also for reducing major cardiovascular risks, including heart attack, stroke, and cardiovascular-related death in individuals with obesity or overweight.
Wegovy®, containing the active ingredient Semaglutide, is available in five dosing strengths and comes in an easy-to-use pen device. The India-specific pricing includes the same cost for the first three doses, supporting smooth dosage escalation without additional financial burden. Clinical studies have shown that 1 in 3 patients may achieve over 20% weight loss when combined with lifestyle changes, alongside a 20% reduction in major cardiovascular events.
In Kolkata, where obesity rates are rising due to urban lifestyle shifts, medical professionals have welcomed the launch. Doctors say the availability of Wegovy® may offer a much-needed tool for long-term obesity management, especially in high-risk populations. “Obesity is a chronic disease and a national epidemic,” said Vikrant Shrotriya, Managing Director of Novo Nordisk India. “Wegovy® represents a transformative, evidence-based solution for India.”